1. Home

REVLIS

REVLIS is committed to the development of digital health management. It uses unique sensors and big data to measure a variety of physiological indexes bases on ECG. It is a more innovative technology than invasion (non-invasion) blood glucose measurement.

AnnJi

Annji is the only clinical – stage new drug development company focusing on the development of innovative small molecules (NCE).

Free Bionics

Free Bionics is the first R&D and design company in Taiwan dedicated to the development of exoskeleton bionic technology products. Provides development and sales of wearable exoskeleton robots and exoskeleton training course.

WINCOAT(WCC)

WCC was established in 2004. As the world’s leading provider of biomedical product, the company has developed a precise and advanced platform – WINMAPTM, to provide customers with high- quality customized microneedle patches or Microarray Patch.

CHO PHARMA INC

CHO PHARMA INC is a Taiwanese biotech company founded in 2013 by a team of distinguished leaders in glycobiology. The company is dedicated to translating cutting-edge science into world-class therapeutics. Through its advanced glycoengineering platform, CHOptimax™, GlycoSyn has developed CHO-H01, the world’s first glycoengineered biobetter with homogeneous glycosylation. This includes SAR-based glycoengineered biobetters, glycan site-specific antibody-drug conjugates (ADCs), and novel vaccines. CHO PHARMA INC is committed to creatively delivering more promising drugs to patients in need.

Anivia Meidical Holding

Anivia is primarily engaged in the manufacturing and sales of implantable medical devices. The company has developed its own core technology platform for extracorporeal circulation, leading to the creation of ECMO systems, extracorporeal circulation devices, brain protection temperature control systems, and related consumables for cardiovascular disease treatment.

ANYA Biopharm INC

ANYA Biopharm INC specializes in excipient combination technology and has developed the MIRA/JE oral peptide platform. This platform enables formulation improvements for small molecule drugs, such as peptides, allowing injectable-only active pharmaceutical ingredients (APIs) to be converted into oral medications while maintaining comparable pharmacokinetics and bioequivalence.